Loved this. Makes me wonder if the next frontier isn’t just GLP-1 expansion, but a broader appetite to tackle adjacent high-cost conditions like SUD. MAT has saved lives, but the system still fails too many — feels like we’re overdue for a step change in addiction care.
Thanks, David. IMO the downstream effects of GLP-1s on addiction is the most exciting area of research taking place right now. Scoring high on impulsiveness is associated with several behavioural conditions all of which are damaging to society. We need to have honest conversations (like, yesterday) on how the hell we make this drug accessible to everyone who may need it (once trial data proves efficacy for SUD).
Loved this. Makes me wonder if the next frontier isn’t just GLP-1 expansion, but a broader appetite to tackle adjacent high-cost conditions like SUD. MAT has saved lives, but the system still fails too many — feels like we’re overdue for a step change in addiction care.
Thanks, David. IMO the downstream effects of GLP-1s on addiction is the most exciting area of research taking place right now. Scoring high on impulsiveness is associated with several behavioural conditions all of which are damaging to society. We need to have honest conversations (like, yesterday) on how the hell we make this drug accessible to everyone who may need it (once trial data proves efficacy for SUD).
Are you aware if there have been any similar brain scan studies on retatrutide as the tirzeptitide cited? Fascinating!